The consequences
of hyperkalaemia

Hyperkalaemia is unpredictable, may often reoccur, and the consequences may be life-threatening.1,2

This website provides healthcare professionals (HCPs) with information on the impact of hyperkalaemia in these high-risk patients, including the effect on RAASi (renin-angiotensin-aldosterone system inhibitors) dosing and clinical outcomes

This site is for non-US, non-UK healthcare professionals only.

References:

  1. Thomsen RW et al. Nephrol Dial Transplant. 2017: 1–10. [Epub ahead of print]
  2. UK Renal Association Clinical Practice Guidelines. 2014. Treatment of Acute Hyperkalaemia in Adults.
Green Kidney icon

Chronic
kidney disease

Hyperkalaemia can be a recurrent problem in patients with CKD, which is associated with an increased risk of hospitalisation*1 and mortality.**2  

*Compared to matched cohorts without hyperkalaemia.

**Compared to a normokalaemia range K+≥3.5-5 mEq/L.

References:

  1. Thomsen RW et al. Nephrol Dial Transplant. 2017: 1–10.
  2. Qin L, et al. ERA-EDTA, Madrid, 2017. Poster presentation MO067.
Orange Heart icon

Heart failure

Hyperkalaemia is common in patients with heart failure, which can prevent patients achieving guideline recommended RAASi.1-3 

*RAASi, renin-angiotensin-aldosterone system inhibitors

References:

  1. Nilsson E, et al. ERA-EDTA, Madrid, 2017. Poster presentation SP313.
  2. Epstein M et al. Am J Manag Care 2015; 21: S212-S220.
  3. Maggioni AP et al. Eur J Heart Fail. 2013; 15: 1173-84.
Co-morbid conditions

Co-morbid
conditions

Some co-morbid conditions increase  a patient’s risk of developing  hyperkalaemia, which is associated  with poor clinical outcomes.1,2 

  1. Thomsen RW et al. Nephrol Dial Transplant. 2017: 1–10. [Epub ahead of print]
  2. Qin L, et al. ERA-EDTA, Madrid, 2017. Poster presentation MO067.
Blue Pill icon

RAASi therapy

Hyperkalaemia and subsequent  suboptimal RAASi treatment is associated with increased morbidity and mortality. *1

*Compared to optimal RAASi treatment

RAASi, renin-angiotensin-aldosterone system inhibitors

References:

  1. Epstein M et al. Am J Manag Care 2015; 21: S212-S220.

There is a need for
additional treatment
options
for the management
of hyperkalaemia.1

Click the links below to discover the impact of
hyperkalaemia on patients with different conditions.

  1. National Kidney Foundation. 2014. Clinical update on hyperkalaemia.